Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Prophylaxis and treatment of deep vein thrombosis (DVT),Prophylaxis and treatment of pulmonary embolism (PE),Anticoagulation for atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, myocardial infarction),Anticoagulation in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is dose-dependent: 0.5–1.5 hours after intravenous administration of 100 U/kg, increasing to 1.5–2.5 hours after 200 U/kg, and up to 3–6 hours after 400 U/kg. Clinically, the anticoagulant effect (a PTT) has a half-life of approximately 1–2 hours, and this is used for dosing adjustments.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Heparin is primarily cleared via the reticuloendothelial system and undergoes desulfation and depolymerization. A portion is excreted unchanged in urine.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: Heparin is primarily cleared by the reticuloendothelial system and the liver via desulfation and depolymerization, with metabolites excreted in urine. Only about 50% of an administered dose is excreted unchanged in urine at therapeutic doses; the remainder is metabolized. Biliary/fecal excretion is minimal.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Heparin binds extensively to various plasma proteins, including antithrombin III (high affinity), albumin, and other proteins. Overall protein binding is approximately 95%.
Low protein binding; 0–11% bound, primarily to albumin.
0.06–0.07 L/kg (low, as heparin is largely confined to the intravascular space).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Subcutaneous: approximately 30–40% (low due to poor absorption and metabolism at injection site). Intravenous: 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific GFR-based dose adjustment required; monitor a PTT. In severe renal impairment (Cr Cl <30 m L/min), reduce infusion rate by 20-50% and monitor anti-Xa levels.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% with close a PTT monitoring. Child-Pugh Class C: Avoid or use with extreme caution; reduce dose by 50-75%.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
IV bolus: 50-100 units/kg, then continuous IV infusion: 15-25 units/kg/hour. Titrate to a PTT 60-85 seconds or anti-Xa 0.3-0.7 units/m L.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients may have reduced clearance; use lower initial infusion rates (e.g., 750 units/hour) and monitor a PTT frequently. Start with 50% of the usual bolus dose in patients >70 years.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Heparin is not intended for intramuscular use due to risk of hematoma. Monitor for signs of bleeding, especially in patients with risk factors. Epidural or spinal hematomas may occur with concurrent neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hemorrhage: monitor coagulation parameters (a PTT) and adjust dose accordingly.,Heparin-induced thrombocytopenia (HIT): monitor platelet counts; discontinue if HIT suspected.,Hyperkalemia: heparin suppresses aldosterone synthesis; monitor potassium in high-risk patients.,Osteoporosis with long-term use ( >3 months).,Use with caution in patients with severe hepatic or renal impairment, uncontrolled hypertension, or history of gastrointestinal ulcers.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Active major bleeding (e.g., intracranial, gastrointestinal, retroperitoneal),History of heparin-induced thrombocytopenia (HIT),Severe thrombocytopenia (platelet count <100,000/µL),Hypersensitivity to heparin or porcine products,Known coagulation disorders (e.g., hemophilia, von Willebrand disease),Inability to perform appropriate coagulation monitoring (e.g., a PTT)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. However, avoid excessive alcohol consumption as it may increase bleeding risk. Vitamin K-rich foods (e.g., leafy greens) do not affect heparin's anticoagulant effect, in contrast to warfarin.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk of major malformations. Second and third trimesters: No known teratogenic effects; use for treatment or prevention of thrombosis is considered safe. Risk of maternal hemorrhage and placental abruption exists with overdose.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Heparin is not excreted into breast milk due to its high molecular weight and negative charge, making it compatible with breastfeeding. M/P ratio is not applicable as it is undetectable in milk.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy is associated with increased plasma volume, renal clearance, and heparin-binding proteins, which may reduce heparin efficacy. Dose adjustment is often required: a PTT monitoring is mandatory, and doses are typically increased (up to 30-50% higher) to maintain therapeutic levels. Weight-based dosing should account for actual body weight. Postpartum, doses may need reduction due to normalization of clearance.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Use actual body weight for dosing; check a PTT 6 hours after initiation and after dose changes; monitor platelet count for heparin-induced thrombocytopenia (HIT); avoid intramuscular injections during therapy. Protamine sulfate (1 mg per 100 units heparin) reverses effects. For I. V. flushes, use preservative-free formulation when possible.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Inform all healthcare providers (including dentists) that you are on heparin.,Do not take any new medications without consulting your doctor.,Seek medical help if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.